Recently, targeted therapies, including inhibitors of c-KIT, NRAS/MEK or BRAF, and immunotherapies, including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies, have revolutionized the treatment of cutaneous melanoma. The gene discussed is NRAS; the disease is cutaneous melanoma.